EUVIMEDEUVIMED entdecken
Crossref

Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation

Rita Brás, Célia Costa, Rita Limão, Leonor Esteves Caldeira, Marisa Paulino, Elisa Pedro

The Journal of Allergy and Clinical Immunology: In Practice · 2023-08 · 11 (8) · 2392-2402

DOI: 10.1016/j.jaip.2023.01.022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2023-08. Verfasst von Rita Brás und 5 weiteren Autor:innen. Beteiligte Einrichtung: Immunoallergology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal. Electronic address: ritasabras…. Hauptthemen laut MEDLINE: Anti-Allergic Agents, Chronic Urticaria, Urticaria, Angioedema. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Allergic AgentsChronic UrticariaUrticariaAngioedemaHumansFemaleMiddle AgedMaleOmalizumabRetrospective StudiesChronic DiseaseTreatment Outcome

Stichwörter der Autor:innen

Anti-IgEChronic spontaneous urticariaOmalizumabTreatment

Substanzen

OmalizumabAnti-Allergic Agents

Autor:innen und Institutionen

  • Immunoallergology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal. Electronic address: ritasabras@gmail.com.
  • Immunoallergology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal. Electronic address: dra.celiacosta.73@gmail.com.
  • Immunoallergology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.

Zitieren

APA

Brás, R., Costa, C., Limão, R., Caldeira, L. E., Paulino, M., & Pedro, E. (2023). Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation. The Journal of Allergy and Clinical Immunology: In Practice, 11(8), 2392-2402. https://doi.org/10.1016/j.jaip.2023.01.022

Vancouver

Brás R, Costa C, Limão R, Caldeira LE, Paulino M, Pedro E. Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation. The Journal of Allergy and Clinical Immunology: In Practice. 2023;11(8):2392-2402. doi:10.1016/j.jaip.2023.01.022

BibTeX
@article{Brs2023,
  author = {Brás, Rita and Costa, Célia and Limão, Rita and Caldeira, Leonor Esteves and Paulino, Marisa and Pedro, Elisa},
  title = {Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2023},
  volume = {11},
  number = {8},
  pages = {2392--2402},
  doi = {10.1016/j.jaip.2023.01.022}
}
Kostenlos starten →